ATAI Life Sciences N.V (ATAI) concluded trading on Thursday at a closing price of $1.60, with 4.58 million shares of worth about $7.32 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 25.00% during that period and on Thursday the price saw a gain of about 20.30%. Currently the company’s common shares owned by public are about 167.82M shares, out of which, 117.06M shares are available for trading.
Stock saw a price change of 30.08% in past 5 days and over the past one month there was a price change of -5.33%. Year-to-date (YTD), ATAI shares are showing a performance of 20.30% which decreased to -5.33% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.03 but also hit the highest price of $2.85 during that period. The average intraday trading volume for ATAI Life Sciences N.V shares is 1.42 million. The stock is currently trading 16.58% above its 20-day simple moving average (SMA20), while that difference is up 14.89% for SMA50 and it goes to 6.93% higher than SMA200.
ATAI Life Sciences N.V (NASDAQ: ATAI) currently have 167.82M outstanding shares and institutions hold larger chunk of about 7.12% of that.
The stock has a current market capitalization of $268.49M and its 3Y-monthly beta is at 1.19. It has posted earnings per share of -$0.80 in the same period. It has Quick Ratio of 5.81 while making debt-to-equity ratio of 0.16. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ATAI, volatility over the week remained 10.88% while standing at 8.91% over the month.
Stock’s fiscal year EPS is expected to drop by -217.14% while it is estimated to increase by 21.17% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on November 18, 2024 offering a Buy rating for the stock and assigned a target price range of between $15 and $10 to it. Coverage by Maxim Group stated ATAI Life Sciences N.V (ATAI) stock as a Buy in their note to investors on April 03, 2024, suggesting a price target of $6 for the stock. On November 01, 2022, Loop Capital Initiated their recommendations, while on November 30, 2021, Maxim Group Initiated their ratings for the stock with a price target of $25. Stock get a Buy rating from ROTH Capital on November 11, 2021.
